Brown Brothers Harriman & CO Incyte Corp Transaction History

Brown Brothers Harriman & CO

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$60.95 - $75.51 $121 - $151	-2 Reduced 18.18%	9 $0
Q1 2023 May 11, 2023	SELL	$70.23 - $86.01 $4,003 - $4,902	-57 Reduced 83.82%	11 $0
Q3 2022 Nov 10, 2022	BUY	$66.18 - $82.86 $595 - $745	9 Added 15.25%	68 $5,000
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $3,904 - $4,907	59 New	59 $4,000
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $2,076 - $2,275	-26 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$76.02 - $100.5 $1,976 - $2,613	26 New	26 $2,000
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $1,453 - $1,758	-18 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $1,335 - $1,960	18 New	18 $2,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $2,211 - $3,008	-35 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $1,893 - $2,249	26 Added 288.89%	35 $3,000
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $3,823 - $4,612	-52 Reduced 85.25%	9 $1,000
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $3,877 - $5,378	61 New	61 $5,000
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $3,073 - $3,736	-37 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $2,245 - $2,798	24 Added 184.62%	37 $4,000
Q2 2017 Aug 14, 2017	BUY	N/A	13	13 $2,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

Stay updated on Brown Brothers Harriman & CO with notifications on news.